Dual Action Hormone Therapy Targeting Two Parts of Androgen Receptor for mCRPC

[Maxone73]

Phase I/II trial of masofaniten combined with enzalutamide, a novel hormonal therapy for mCRPC. Masofaniten, a first-in-class N-terminal ligand antagonist for the androgen receptor, shows promise in overcoming resistance to current hormonal therapies.

Hopefully a new weapon for us!

[KocoPr]

I have always been excited about the N-Terminal ligand antagonists.

You stop that and you stop all Androgen transcription. I can see that as not a permanent treatment but a short treatment to kill all of your cancer that is androgen dependent before it mutates to a non-androgen status like neuroendicrine.

[KocoPr]

So the key is hit it early before Castrate Resistance and you may have a cure. Hit it after you become CRPC and you certainly can extend survival.

[Maxone73 in reply to KocoPr]

I hope we will have an answer while I am still hormone sensitive!

[KocoPr in reply to Maxone73]

I believe AI might find a natural or off use cheap drug to treat nhibit the N-Terminal domain

[Maxone73 in reply to KocoPr]

Pipeline, the problem is that since we are more precise and with less probability of people dying while testing a new discovery (we are always talking about probability in medicine), time from phase 1 to phase 4 should be shortened IMO. Knowledge is increasing exponentially in both new discoveries and repurposing (for obvious reasons the biggest money goes into creating new drugs) 😀

[fmenninger]

this looks very promising as it begins phase 2 trials. Are they recruiting at mskcc?

[Maxone73 in reply to fmenninger]

I would suppose so as dr Laccetti is from msk 😀

[Ramp7]

Very interesting!